■ 学術雑誌
|
原著
|
|
1.
|
Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller KD, Kao S,
Kongpachith S, Tribouley C, Graham M, Stoll B, Patel M, Sahtout M, Blaney M,
Leibman R, Golan T, Tolcher A.：
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
Frontiers in oncology
14
：1376551
, 2024
|
|
